PT Kimia Farma (Persero) Tbk (KAEF.JK)
IDR 600.0
(-0.83%)
IDR 600.0
(-0.83%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 9965.03 Billion | 9606.14 Billion | 12857.62 Billion | 10006.17 Billion | 9400.53 Billion | 7454.11 Billion |
| Cost of Revenue | 7184.76 Billion | 6013.31 Billion | 8461.34 Billion | 6349.04 Billion | 5897.24 Billion | 4673.93 Billion |
| Gross Profit | 2780.27 Billion | 3592.83 Billion | 4396.28 Billion | 3657.13 Billion | 3503.28 Billion | 2780.17 Billion |
| Operating Expenses | 4350.51 Billion | 3240.75 Billion | 3471.7 Billion | 3164.02 Billion | 3211.85 Billion | 2183.97 Billion |
| Selling, General and Administrative Expenses | 4027.63 Billion | 991.4 Billion | 1029.34 Billion | 1168.44 Billion | 1425.05 Billion | 829.02 Billion |
| Research and Development Expenses | 97.04 Billion | 46.36 Billion | 41.34 Billion | 15.52 Billion | 15.32 Billion | 18.06 Billion |
| Other Expenses | 225.84 Billion | 2202.99 Billion | 2401 Billion | 1980.05 Billion | 1771.47 Billion | 118.83 Billion |
| Cost and Expenses | 11535.28 Billion | 9254.06 Billion | 11933.04 Billion | 9513.07 Billion | 9109.1 Billion | 6857.91 Billion |
| Operating Income | -1570.24 Billion | 558.07 Billion | 985.63 Billion | 653.02 Billion | 501.65 Billion | 765.01 Billion |
| Interest Expense | 622.81 Billion | 520.6 Billion | 606.81 Billion | 596.37 Billion | 497.96 Billion | 187.29 Billion |
| Income Tax Expense | -365.57 Billion | 143.94 Billion | 102.99 Billion | 52.93 Billion | 22.42 Billion | 175.93 Billion |
| Earnings before Tax | -2167.61 Billion | 49.62 Billion | 392.88 Billion | 73.35 Billion | 38.31 Billion | 577.72 Billion |
| Net Income | -1485.56 Billion | -94.32 Billion | 302.27 Billion | 17.63 Billion | 15.89 Billion | 415.89 Billion |
| Earnings Per Share Basic | -267.48 | -16.98 | 54.42 | 3.18 | 2.86 | 74.88 |
| Earnings Per Share Diluted | -267.48 | -16.98 | 54.42 | 3.18 | 2.86 | 74.88 |
| Weighted Average Shares Outstanding | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion |
| Weighted Average Shares Outstanding (Diluted) | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion | 5.55 Billion |
| Gross Margin | 0.28 | 0.37 | 0.34 | 0.37 | 0.37 | 0.37 |
| EBIT Margin | -0.12 | 0.08 | 0.10 | 0.08 | 0.06 | 0.11 |
| Profit Margin | -0.15 | -0.01 | 0.02 | 0.00 | 0.00 | 0.06 |
| EBITDA | -1223.64 Billion | 1019.74 Billion | 1391.47 Billion | 914.09 Billion | 695.94 Billion | 1161.03 Billion |
| Earnings Before Tax Margin | -0.16 | 0.06 | 0.08 | 0.07 | 0.05 | 0.10 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 2650.56 Billion | 2677.91 Billion | 2535.77 Billion | 2249.75 Billion | 9965.03 Billion | 2768.83 Billion |
| Cost of Revenue | 1992.21 Billion | 1919.07 Billion | 1714.94 Billion | 1975.08 Billion | 7155.17 Billion | 1779.65 Billion |
| Gross Profit | 658.34 Billion | 758.84 Billion | 820.83 Billion | 274.67 Billion | 2809.86 Billion | 989.18 Billion |
| Operating Expenses | 794.38 Billion | 890.06 Billion | 855.39 Billion | 1883.13 Billion | 4371.74 Billion | 1045.72 Billion |
| Selling, General and Administrative Expenses | 771.45 Billion | 243.8 Billion | 251.28 Billion | 1623.11 Billion | - | 351.22 Billion |
| Research and Development Expenses | 12.9 Billion | 5.6 Billion | 6.75 Billion | 48.12 Billion | - | 16.19 Billion |
| Other Expenses | -10.03 Billion | 6.07 Billion | 14.27 Billion | -211.88 Billion | -243.14 Billion | 70.74 Billion |
| Cost and Expenses | 2786.6 Billion | 2809.13 Billion | 2570.33 Billion | 3858.21 Billion | 11526.91 Billion | 2825.37 Billion |
| Operating Income | -136.03 Billion | -40.45 Billion | -20.95 Billion | -1608.45 Billion | -1561.88 Billion | 4.28 Billion |
| Interest Expense | 141.77 Billion | 155.07 Billion | 145.39 Billion | 212.44 Billion | 622.81 Billion | 153.81 Billion |
| Income Tax Expense | -37.04 Billion | -23.49 Billion | -22.27 Billion | -346.21 Billion | -365.57 Billion | -15.53 Billion |
| Earnings before Tax | -275.67 Billion | -193.86 Billion | -164.11 Billion | -2017.98 Billion | -2167.61 Billion | -146.69 Billion |
| Net Income | -195.05 Billion | -124.04 Billion | -102.73 Billion | -1308.19 Billion | -1485.56 Billion | -155.6 Billion |
| Earnings Per Share Basic | -35.04 | -22.30 | -18.47 | -235.54 | - | -27.97 |
| Earnings Per Share Diluted | -35.04 | -22.30 | -18.47 | -235.54 | - | -27.97 |
| Weighted Average Shares Outstanding | 5.56 Billion | 5.56 Billion | 5.56 Billion | 5.55 Billion | 5.55 Billion | 5.56 Billion |
| Weighted Average Shares Outstanding (Diluted) | 5.56 Billion | 5.56 Billion | 5.56 Billion | 5.55 Billion | 5.55 Billion | 5.56 Billion |
| Gross Margin | 0.25 | 0.28 | 0.32 | 0.12 | 0.28 | 0.36 |
| EBIT Margin | -0.00 | 0.02 | 0.02 | -0.59 | - | 0.03 |
| Profit Margin | -0.07 | -0.05 | -0.04 | -0.58 | -0.15 | -0.06 |
| EBITDA | -735.32 Million | 55.13 Billion | 61.64 Billion | -1335.93 Billion | - | 84.26 Billion |
| Earnings Before Tax Margin | -0.05 | -0.02 | -0.01 | -0.71 | -0.16 | 0.00 |
0288
CANDOUR
OMIC
NBTX
GABI
GANGESSECU